Results 271 to 280 of about 1,029,823 (374)

Exploring entropy measures in polymer graphs using logarithmic regression model. [PDF]

Sci Rep
Irfan M, Younis J, Altassan A, Alfwzan WF, Bashir N, Alharbi NT.   +5 more
europepmc   +1 more source

Cylindrical algebraic decomposition based methods in satisfiability modulo non-linear real arithmetic

Nalbach, Jasper Kurt Ferdinand
openalex   +1 more source

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First‐in‐Human Randomized, Double‐Blind, Placebo‐Controlled Single Ascending Dose Escalation Phase 1 Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective 5‐hydroxytryptamine 2C (5‐HT2C) superagonist in development for the treatment of seizures in developmental and epileptic encephalopathies (DEEs). This double‐blind, placebo‐controlled, single ascending dose (SAD) Phase 1 study aimed to assess the safety, tolerability, and pharmacokinetic (PK) and ...
Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R Srinivas, Randall Kaye   +6 more
wiley   +1 more source

Impact of flipped classroom strategy and learning on the acquisition of basic skills among students in the basketball 1 course at Birzeit University. [PDF]

Front Sports Act Living
Yousef I, Kayed M, Liftawi S, Hamdan S, Alnuaimi J, Al-Kilani H.   +5 more
europepmc   +1 more source

On perform arithmetic operations in negative binary system

, 2008
Володимир Петрович Тарасенко, І. Ю. Король   +1 more
openalex   +1 more source

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective superagonist of the 5‐hydroxytryptamine 2C (5‐HT2C) receptor currently in development for the treatment of seizures that arise from developmental and epileptic encephalopathies. This phase 1, double‐blind, placebo‐controlled multiple ascending dose (MAD) study assessed the safety, tolerability, and ...
Jonathan Williams, Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R. Srinivas, Randall Kaye   +7 more
wiley   +1 more source

A compact and power efficient full adder-subtractor layout in QCA technology. [PDF]

PLoS One
Majeed AH.
europepmc   +1 more source

A Comparative Study of Intelligence Quotients and Achievement Scores and Marks in Social Studies, Arithmetic, Physical Education, Elementary Science, and Language Arts in the Sixth Grade of Wolflin School, Amarillo

, 1946
Ruby Gray Peters
openalex   +1 more source

A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG‐055009, a novel thyroid hormone receptor beta (THR‐β) agonist for metabolic dysfunction‐associated steatohepatitis (MASH), in healthy participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract ALG–055009 is an oral thyroid hormone receptor beta (THR‐β) agonist being evaluated for treating metabolic dysfunction–associated steatohepatitis (MASH). This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALG‐055009 and bioavailability/food effect.
Hakim Charfi, Benedetta Massetto, Megan Fitzgerald, Kha Le, Stanley Wang, Ifong Kan‐Eng, Meenakshi Venkatraman, Naqvi Mohammad, Lawrence Blatt, Tse‐I Lin, Sushmita M. Chanda, John Fry   +11 more
wiley   +1 more source

Optimized fall detection using hybrid BiLSTM BiGRU additive attention model and BAOA driven feature selection system. [PDF]

Sci Rep
Ahirwar MS, Soni V.
europepmc   +1 more source